This study will evaluate the safety and tolerability of MK6186 and the change from baseline in plasma HIV-1 RNA after seven consecutive days of dosing.

Inclusion Criteria:

• Other than HIV infection, patient's baseline health is judged to be stable
• Patient is documented HIV-1 positive
• Patient has not received an investigational agent or licensed ART with in the past 30 days

Exclusion Criteria:

• Patient has a history of stroke, chronic seizures, or major neurological disease
• Patient has a history of cancer
• Patient has used any immune therapy agents or immunosuppressive therapy within the past month
• Patient requires or anticipates the use of any prescription or non-prescription drugs during the study
• Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or has positive Hepatitis B surface antigen
• Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day)
• Patient is an excessive smoker (more than 10 cigarettes per day)
• Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks